#South Korea #Seoul #Global Bio Conference #K-Bio #MFDS

Global Bio Conference 2026: Accelerating Innovation in Bio Industry Worldwide

Global Bio Conference 2026: Accelerating Innovations in Bio

The Global Bio Conference 2026 (GBC 2026) is set to take place from August 26 to 28, 2026, at the Grand InterContinental Seoul Parnas in Gangnam-gu, Seoul, under the theme "The Great Leap in Bio, Accelerating Innovation." Organised by the Ministry of Food and Drug Safety of Korea (MFDS), this year's conference aims to highlight the essential role of regulation in facilitating the rapid development of groundbreaking biopharmaceuticals and technologies, bridging the gap between innovation and real-world applications.

A Gathering of Global Experts

With its 12th edition, GBC 2026 is expected to attract around 5,000 participants, including regulatory officials, industry leaders in pharmaceuticals and biotechnology, and academic experts from across the globe. The event will serve as a platform for these stakeholders to share insights on the latest technological advancements, industry trends, and regulatory policies.

A highlight of this year’s conference will be the newly established session named "K-BIO Innovation Leaders Talk." This initiative will showcase influential figures in Korea’s bio sector, who will discuss their personal experiences and strategies for navigating the challenges of entering and succeeding in global markets. This discussion aims to inspire further innovation and collaboration.

Opening Ceremony and Keynote Insights

The first day of the conference will commence with an opening ceremony featuring prominent guests, including President Lee Jae-myung and Vice Speaker of the National Assembly, Nam In-soon. These dignitaries will provide congratulatory remarks underscoring the importance of the bio industry as a critical engine for future economic growth.

The keynote session will see an array of esteemed speakers, including

- Lee Sang Yup (Distinguished Professor, KAIST),
- Jeremy Farrar (Assistant Director-General, WHO),
- Azad Bonni (Senior VP, Roche pRED), and
- David Nogales (Head of Technology Strategy, Merck KGaA).

These experts will share their perspectives on the trends driving biopharmaceutical innovations, regulatory adaptations, and insights on future industrial transformations.

Specialized Forums and Workshops

In the following days, attendees can engage in specialized forums focusing on critical areas such as vaccines, recombinant protein products, and biopharmaceutical supply chains. Each forum will address urgent topics such as:

- Vaccine Forum: Reviewing post-authorization safety management practices and evaluating emerging vaccine technologies.
- Recombinant Protein Products Forum: Exploring AI's role in antibody therapy development and discussing new approaches to regulatory evidence requirements.
- Biopharmaceutical Supply Chain Forum: Strategies to mitigate supply chain disruptions exacerbated by crises, including geopolitical issues and pandemics.

Moreover, the Regulatory Science Innovation Forum will introduce the latest strategies adopted by MFDS to accelerate new drug approvals, encouraging dialogues between regulators and the development community on creating a more efficient regulatory environment.

Workshops will dive into alternative testing methods to replace animal testing in biopharmaceuticals, facilitating dialogue on advancements in the regulatory landscape. Another initiative, Mentoring for Bio Youths, aims to empower the next generation of bio professionals through guidance and support.

International Collaboration and Regulatory Innovations

The conference will also mark significant discussions on global regulatory cooperation, focusing on uniting regulatory practices across borders for expedited biopharmaceutical advancements. Notably, the Regulatory Workshop will illustrate how diverse regulatory authorities intend to foster innovation through supportive frameworks, addressing the need for adaptable regulations amid evolving biotechnologies.

In a series of collaboration meetings, international regulators will meet with Korean companies to foster a shared understanding and facilitate market entry for Korean biopharmaceuticals on a global scale. This will include joint workshops examining the regulatory environment for groundbreaking products such as cell and gene therapies.

Conclusion

Minister Oh Yu-Kyoung of the MFDS remarked that the bio industry is rapidly transforming and continuously introducing innovative technologies. She emphasized that the ability to convert the potential for innovation into tangible results is key to maintaining competitive advantages. GBC 2026 is anticipated to serve as a crucial step in sharing invaluable experiences and insights among regulatory bodies, academia, and industry, propelling South Korea toward its vision of becoming a global leader in biopharmaceutical innovation. MFDS aims to leverage this conference as a stepping stone toward strengthening international cooperation and ensuring that Korea's groundbreaking biopharmaceutical innovations reach the worldwide market efficiently.